Novartis Terminates Collaboration on NASH Therapy PLN-1474 with Pliant Therapeutics

On February 23, Pliant stated in an SEC filing that Novartis had terminated the collaboration to develop PLN-1474, an integrin αVβ1 inhibitor for the treatment of non-alcoholic steatohepatitis (NASH), as part of its strategic decision to discontinue developing NASH therapies. The termination agreement will take effect on April 18, 2023.

Novartis' collaboration with Pliant began in October 2019. At that time, Novartis committed to paying Pliant an upfront payment of $50 million and up to $416 million in future milestone payments to acquire the development and commercialization rights for PLN-1474 and three additional integrin candidate products. To date, Pliant has received $29 million in milestone payments.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reprint, please leave a message or send a notification to the WeChat Official Account backend, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.